INTRODUCTION
============

Conditional transcription control systems which fine-tune heterologous transgene expression in mammalian cells are fundamental for gene-function analysis ([@B1],[@B2]), drug discovery ([@B3],[@B4]), expression dosing in gene therapy ([@B5]), design of synthetic gene networks and for manufacturing of difficult-to-produce protein pharmaceuticals ([@B6],[@B7]). Currently available mammalian transgene control systems capitalize on a generic design consisting of a synthetic transactivator (transrepressor), typically derived from a prokaryotic response regulator fused to a mammalian transactivation (transrepression) domain and a chimeric promoter assembled by cloning transactivator-specific operator sites adjacent to a minimal (constitutive) eukaryotic promoter ([@B8; @B9; @B10]). Binding of an inducer molecule modulates the affinity of the transactivator (transrepressor) for the cognate promoter and either induces (ON-type systems, ([@B11; @B12; @B13; @B14])) or represses (OFF-type systems, ([@B14],[@B15])) transcription of linked transgenes. Trigger molecules and parameters include antibiotics ([@B10],[@B14],[@B16]), hormones and hormone analogs ([@B17; @B18; @B19]), quorum sensing substances ([@B12],[@B20],[@B21]), temperature ([@B22]), the redox poise ([@B20]), immunosuppressive and antidiabetic drugs ([@B23],[@B24]), gaseous acetaldehyde ([@B11]) and biotin ([@B25]). Although most of these established gene regulation systems show excellent regulation performance *in vitro* as well as in animals, the inducer molecules are often incompatible with gene therapy and biopharmaceutical manufacturing scenarios because of their side-effects, which are well documented for hormones and some of their analogs ([@B26],[@B27]), antibiotics ([@B28; @B29; @B30]) and immunosuppressive drugs ([@B31],[@B32]). While the biopharmaceutical manufacturing industry strives to develop gene regulation systems controlled by FDA-approved media components to prevent prohibitive downstream processing and licensing procedures ([@B33]), the gene therapy community dreams of capturing pathologic signals which can be converted into a well-tuned therapeutic intervention. The common interest is exploiting physiologic signal molecules for titration of heterologous product gene expression and prevent interference between endogenous and synthetic regulatory circuits.

As an obligate intracellular pathogen infecting the respiratory tracts and causing pneumonia and atherosclerotic heart disease ([@B34; @B35; @B36; @B37]), *Chlamydia pneumoniae* has evolved to capture physiologic signals and synchronize its metabolism with the host cell ([@B38]). For example, the coordination of arginine biosynthesis and catabolism with availability of this amino acid in host cells is managed by ArgR, a master regulatory molecule acting as an arginine-dependent apo-repressor that specifically binds to arginine-responsive transactivator (ARG) box operators anzd represses the *glnPQ* operon which encodes a putative arginine transport system in an arginine-responsive manner ([@B39],[@B40]). ArgR, which is highly conserved in bacterial systems, can function both as transcriptional repressor or activator ([@B41],[@B42]). In *Escherichia coli*, ArgR negatively regulates the expression of the arginine biosynthetic genes in response to intracellular [l]{.smallcaps}-arginine levels ([@B43]). When acting as a repressor, ArgR requires allosteric activation by [l]{.smallcaps}-arginine to bind to an 18-bp palindromic operator sequence known as the ARG box ([@B39],[@B43; @B44; @B45]). While the N-terminal half of ArgR contains a winged helix-turn-helix family DNA binding domain, the C-terminal half is responsible for arginine binding.

We have engineered ArgR and the ARG box of *C. pneumoniae* for [l]{.smallcaps}-arginine-regulated transgene (ART) regulation system in mammalian cells. As an ON-type system by default, ART remained silent at minimal endogenous [l]{.smallcaps}-arginine concentrations and was adjustably induced by increasing [l]{.smallcaps}-arginine levels. Using a proteogenic amino acid to control heterologous transgene in mammalian cells grown in monolayer cultures or in mice should foster new opportunities in gene therapy and biopharmaceutical manufacturing.

MATERIALS AND METHODS
=====================

Plasmid construction
--------------------

All plasmids and oligonucleotides constructed and used in this study are listed in [Table 1](#T1){ref-type="table"}. Details on vector design are also provided in [Table 1](#T1){ref-type="table"}. Table 1.Plasmids and oligonucleotides used and designed in this studyPlasmidDescription and cloning strategyReference or sourcepRevTREOncoretroviral expression vector containing a tetracycline-responsive expression unitClontech, Palo Alto, CA, USApPurSelection vector conferring puromycin resistance to eukaryotic cellsClontech, Palo Alto, CA, USApSV2*neo*Selection vector conferring neomycin resistance to eukaryotic cellsClontech, Palo Alto, CA, USApBP10Vector encoding a P~ETR5~-driven SEAP expression unit (P~ETR5~-SEAP-pA; P~ETR5~, ETR-2bp-P~hCMVmin~)([@B9])pBP11Vector encoding a P~ETR6~-driven SEAP expression unit (P~ETR6~-SEAP-pA; P~ETR6~, ETR-4bp-P~hCMVmin~)([@B9])pBP12Vector encoding a P~ETR7~-driven SEAP expression unit (P~ETR7~-SEAP-pA; P~ETR7~, ETR-6bp-P~hCMVmin~)([@B9])pBP13Vector encoding a P~ETR8~-driven SEAP expression unit (P~ETR8~-SEAP-pA; P~ETR8~, ETR-8bp-P~hCMVmin~)([@B9])pBP14Vector encoding a P~ETR9~-driven SEAP expression unit (P~ETR9~-SEAP-pA; P~ETR9~, ETR-10bp-P~hCMVmin~)([@B9])pMF111Vector encoding a P~hCMVmin~-driven SEAP expression unit (P~hCMVmin~-SEAP-pA)([@B69])pMT1227Vector encoding the *C. pneumoniae* CWL029 *ArgR* gene([@B39])pWW35Constitutive ET1 expression vector (P~SV40~-ET1-pA)([@B10])pWW42Constitutive ET2 expression vector (P~SV40~-ET2-pA)([@B10])pWW64Constitutive ET3 expression vector (P~SV40~-ET3-pA)([@B9])pSH91Constitutive ARG2 expression vector (P~SV40~-ARG2-pA) *argR* was amplified from pMT1227 using OSH49: 5′-gatc*gaattc*ccaccATGA AAAAAAAAGTAAC TATAGATGAGG-3′ and OSH50: 5′-cttatg*gcgcgc*ggctgtacgc ggaATCCAAGAA AACTTGCAGTA AATTTG-3′ (upper case, annealing sequence; lower case italic, restriction sites), digested with *Eco*RI/*BssH*II and ligated into pWW35 (*Eco*RI/*BssH*II).This workpSH92Vector encoding O~ARG~-0bp-P~hCMVmin~-ET1-pA O~ARG~-0bp-P~hCMVmin~ was amplified from pRevTRE using OSH51: 5′-gatc*gacgtcAGTTTTCTTGGATTAATTGCATAAATATGATTTCATTATAAATAAATATGCATAAGAGGTCGGAGTG*cctgcaggTCGAGCTCGGTACCCGGGTC-3′ and OWW22: 5′-gcta*gaattc*CGCGGAGGCTGGATCGG-3′ (upper case, annealing sequence; lower case italic, restriction sites; upper case italic, O~ARG~), digested with *Aat*II/*Eco*RI and ligated into pWW35 (*Aat*II/*Eco*RI).This workpSH93Vector encoding a P~ART1~-driven expression unit (P~ART1~-SEAP-pA; P~ART1~, O~ARG~-0bp-P~hCMVmin~) O~ARG~-0bp-P~hCMVmin~ was excised from pSH92 (*Ssp*I/*Eco*RI) and ligated into pMF111 (*Ssp*I/*Eco*RI).This workpSH105Vector encoding a P~ART2~-driven expression unit (P~ART2~-SEAP-pA; P~ART2~, O~ARG~-2bp-P~hCMVmin~) 2bp-P~hCMVmin~-SEAP was excised from pBP10 (*Sbf*I/*Xho*I) and ligated into pSH93 (*Sbf*I/*Xho*I).This workpSH106Vector encoding a P~ART3~-driven expression unit (P~ART3~-SEAP-pA; P~ART3~, O~ARG~-4bp-P~hCMVmin~) 4bp-P~hCMVmin~-SEAP was excised from pBP11 (*Sbf*I/*Xho*I) and ligated into pSH93 (*Sbf*I/*Xho*I).This workpSH107Vector encoding a P~ART4~-driven expression unit (P~ART4~-SEAP-pA; P~ART4~, O~ARG~-6bp-P~hCMVmin~) 6bp-P~hCMVmin~-SEAP was excised from pBP12 (*Sbf*I/*Xho*I) and ligated into pSH93 (*Sbf*I/*Xho*I).This workpSH108Vector encoding a P~ART5~-driven expression unit (P~ART5~-SEAP-pA; P~ART5~, O~ARG~-8bp-P~hCMVmin~) 8bp-P~hCMVmin~-SEAP was excised from pBP13 (*Sbf*I/*Xho*I) and ligated into pSH93 (*Sbf*I/*Xho*I).This workpSH109Vector encoding a P~ART6~-driven expression unit (P~ART6~-SEAP-pA; P~ART6~, O~ARG~-10bp-P~hCMVmin~) 10bp-P~hCMVmin~-SEAP was excised from pBP14 (*Sbf*I/*Xho*I) and ligated into pSH93 (*Sbf*I/*Xho*I).This workpSH115Vector encoding *Asc*I-O~ARG~-*Mlu*I-0bp-P~hCMVmin~-ET1-pA *Asc*I-O~ARG~-*Mlu*I-0bp-P~hCMVmin~ was amplified from pRevTRE using OSH69: 5′-gatc*gacgtc*ggcgcgcc*AGTTTTCTTGGATTAATTGCATAAATATGATTTCATTATAAATAAATATGCATAAGAGGTCGGAGTG*acgcgtcctgcaggTCGAGCTCGGTACCCGGGTC-3′ and OWW22: 5′-gcta*gaattc*CGCGGAGGCTGGATCGG-3′ (upper case, annealing sequence; lower case italic, restriction sites; upper case italic, O~ARG~), digested with *Aat*II/*Eco*RI and ligated into pWW35 (*Aat*II/*Eco*RI).This workpSH117Vector encoding a P~ARTm1~-driven expression unit (P~ARTm1~-SEAP-pA; P~ARTm1~, *Asc*I-O~ARG~-*Mlu*I-0bp-P~hCMVmin~) *Asc*I-O~ARG~-*Mlu*I-0bp-P~hCMVmin~ was excised from pSH115 (*Ssp*I/*Eco*RI) and ligated into pSH93 (*Ssp*I/*Eco*RI).This workpSH119Vector encoding a P~ARTm2~-driven expression unit (P~ARTm2~-SEAP-pA; P~ARTm2~, *Asc*I-O~ARG~-7bp-O~ARG~-*Mlu*I-0bp-P~hCMVmin~) *Asc*I-O~ARG~-*Mlu*I-0bp-P~hCMVmin~-SEAP was excised from pSH117 (*Asc*I/*Xho*I) and ligated into pSH117 (*Mlu*I/*Xho*I).This workpSH120Constitutive ARG1 expression vector (P~SV40~-ARG1-pA) The NF-κB-derived transcription domain (p65) was excised from pWW42 (*BssH*II/*BamH*I) and ligated into pSH91 (*BssH*II/*BamH*I).This workpSH121Constitutive ARG3 expression vector (P~SV40~-ARG3-pA) The E2F4-derived transcription domain (E2F4) was excised from pWW64 (*BssH*II/*BamH*I) and ligated into pSH91 (*BssH*II/*BamH*I).This workpSH122Autoregulated vector encoding a P~ART1~-driven expression unit (P~ART1~-SEAP-IRES~PV~-ARG2-pA) ARG2 was excised from pSH91 (*NotI*/*Xba*I) and ligated into pSH93 (*Not*I/*Nhe*I).This workpSH126Vector encoding a P~ARTm3~-driven expression unit (P~ARTm3~-SEAP-pA; P~ARTm3~, *Asc*I-O~ARG~-7bp-O~ARG~-7bp-O~ARG~--*Mlu*I-0bp-P~hCMVmin~) *Asc*I-O~ARG~-7bp-O~ARG~--*Mlu*I-0bp-P~hCMVmin~-SEAP was excised from pSH119 (*Asc*I/*Xho*I) and ligated into pSH117 (*Mlu*I/*Xho*I).This workpSH127Vector encoding a P~ARTm4~-driven expression unit (P~ARTm4~-SEAP-pA; P~ARTm4~, *Asc*I-O~ARG~-7bp-O~ARG~-7bp-O~ARG~--7bp-O~ARG~-*Mlu*I-0bp-P~hCMVmin~) *Asc*I-O~ARG~-7bp-O~ARG~--*Mlu*I-0bp-P~hCMVmin~-SEAP was excised from pSH119 (*Asc*I/*Xho*I) and ligated into pSH119 (*Mlu*I/*Xho*I).This work[^1]

Cell culture, transfection and construction of stable cell lines
----------------------------------------------------------------

Wild-type Chinese hamster ovary cells (CHO-K1, ATCC: CCL-61) and its derivatives \[e.g. CHO-ET~1~-SEAP~1~; ([@B10])\] were cultivated in [l]{.smallcaps}-arginine-free ChoMaster® HTS (Cell Culture Technologies, Gravesano, Switzerland) supplemented with 10 mg/l [l]{.smallcaps}-arginine, 5% (v/v) fetal calf serum (FCS, PAN Biotech GmbH, Aidenbach, Germany, Cat. No. 3302, Lot No. P251110) and 1% (v/v) penicillin/streptomycin solution (Sigma, St Louis, MO, USA, Cat. No. P4458). Human fibrosarcoma cells (HT-1080, ATCC, CCL-121), African green monkey kidney cells (COS-7, ATCC CRL-1651) and human embryonic kidney cells, transgenic for the simian virus 40 (SV40) large T antigen \[HEK293-T, ([@B46])\], were cultivated in [l]{.smallcaps}-arginine-free Hektor G (Cell Culture Technologies, Gravesano, Switzerland) supplemented with 10 mg/l [l]{.smallcaps}-arginine, 10% (v/v) FCS and 1% (v/v) penicillin/streptomycin solution. Mouse fibroblasts (NIH/3T3, ATCC: CRL-1658) were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM, Invitrogen, Basel, Switzerland, Cat. No. 52100-39) supplemented with 10% FCS and 1% (v/v) penicillin/streptomycin solution. All cell types were cultivated at 37°C in a humidified atmosphere containing 5% CO~2~.

For DNA transfection, 1.2 μg DNA (for co-transfection an equal amount of each plasmid) was transfected into 55 000 cells pre-cultivated for 24 h in a well of a 24-well plate. For transfection of CHO-K1, the plasmid DNA was diluted into a total volume of 25 μl 0.5 M CaCl~2~ solution, mixed with 25 μl solution (100 mM HEPES, 280 mM NaCl, 1.5 mM Na~2~HPO~4~, pH 7.1) and incubated for 15 min at room temperature. The DNA--calcium phosphate complex was added, and centrifuged onto the cells (5 min at 1200 *g*) to increase transfection efficiency. After incubation for 2 h, the cells were exposed to a glycerol shock for 30 s ([l]{.smallcaps}-arginine-free ChoMaster® HTS medium supplemented with 15% glycerol). After a single washing with phosphate-buffered saline (PBS, Dulbecco\'s phosphate-buffered saline, Invitrogen, Basel, Switzerland, Cat. No. 21600-0069), the cells were cultivated in ChoMaster® HTS supplemented with different [l]{.smallcaps}-arginine concentrations. For transfection of COS-7, HEK293-T, the standard calcium phosphate-based transfection protocol was used ([@B21]) and transfected populations were cultivated in Hektor G supplemented with different [l]{.smallcaps}-arginine concentrations. HT-1080 and NIH/3T3 were transfected with Fugene™ 6 (Roche Diagnostics AG, Basel, Switzerland, Cat. No. 11814443001) following the supplier\'s protocol and cultivated in Hektor G and DMEM, respectively. Production of the reporter protein was assessed in the culture supernatants 60 h after transfection, unless indicated otherwise.

CHO-ARG2-SEAP, transgenic for [l]{.smallcaps}-arginine-controlled SEAP expression, was constructed by sequential co-transfection and clonal selection of (i) pSH91 and pPur (Clontech, Cat. No. 6156-1) (CHO-ARG2) and (ii) pSH93 and pSV2*neo* (Clontech, Cat. No. 6172-1) (CHO-ARG2-SEAP). To assess the dose--response characteristics of ART-regulated gene expression, CHO-ARG2-SEAP was cultured at 110 000 cells/ml for 60 h in [l]{.smallcaps}-arginine-free ChoMaster® HTS supplemented with [l]{.smallcaps}-arginine ranging from 10 mg/l to 10 000 mg/l. Reversibility of [l]{.smallcaps}-arginine-mediated SEAP production was assessed by cultivating CHO-ARG2-SEAP (110 000 cells/ml) for 1 week while alternating [l]{.smallcaps}-arginine concentrations from 10 to 1000 mg/l every 48 h.

Western blot analysis
---------------------

Sixty hours after transfection of 350 000 HEK-293T cells with the vector encoding ARG2 (pSH91, P~SV40~-ARG2-pA), the cell lysate was heat denaturated in 5× SPS-PAGE reducing sample buffer (50% glycerol, 250 mM Tris, 10% sodium dodecylsulfate, 500 mM dithiothreitol, 0.01% bromophenolblue, pH 6.8) at 85°C for 3 min and size-fractionated on a 12% SDS-polyacrylamide gel. The gel was transferred to a polyvinylidene fluoride membrane (Millipore Corporation, Bedford, USA. Cat. No. IPVH20200) and blocked overnight with 5% low fat milk (Migros, Switzerland) in PBS. The target protein was detected with a primary monoclonal anti-VP16 (Santa Cruz Biotechnology Inc., California, Cat. No. sc-7545, 1 : 100 dilution in 5% low fat milk in PBS) and visualized using a secondary HRP-coupled anti-mouse IgG (Amersham Biosciences UK Limited, Buckinghamshire, UK, Cat. No. NA931V, 1 : 1000 dilution in 5% low fat milk in PBS) and a chemiluminescence-based assay (GE Healthcare Amersham UK Limited, Buckinghamshire, UK, Cat. No. RPN2132). Following the same protocol, tubulin-α was visualized as a loading control (Ab-2 (DM1A); Neomarkers, California, Cat. No. MS-581-P1).

Regulating [l]{.smallcaps}-arginine and [l]{.smallcaps}-arginine analogs
------------------------------------------------------------------------

[l]{.smallcaps}-arginine stock solution was prepared in water by adjusting 50 g/l [l]{.smallcaps}-arginine base (0.287 M, AppliChem, Darmstadt, Germany, Cat. No. A3653,0100) to pH 7.2 with HCl and used at the final concentrations indicated. [l]{.smallcaps}-ornithine hydrochloride (Fluka, Buchs, Switzerland, Cat. No. 75470) and [l]{.smallcaps}-citrulline (Fluka, Buchs, Switzerland, Cat. No. 27510), [l]{.smallcaps}-homoarginine hydrochloride (Acros Organics, Basel, Switzerland, Cat. No. 169090050) were dissolved in water (0.287 M) with pH adjusted to 7.2 by NaOH. [l]{.smallcaps}-arginine methyl ester dihydrochloride (Fluka, Buchs, Switzerland, Cat. No. 11030), [l]{.smallcaps}-arginine ethyl ester dihydrochloride (Sigma-Aldrich, Steinheim, Germany, Cat. No. A2883), agmatine sulfate (Sigma-Aldrich, Cat. No. A7127) and [l]{.smallcaps}-canavanine sulfate (Sigma-Aldrich, Cat. No. C9758) stock solutions were prepared by adjusting the pH of a 0.144 M solution to pH 7.2.

Quantification of reporter gene expression
------------------------------------------

Production of the human placental secreted alkaline phosphatase (SEAP) was quantified using a *p*-nitrophenylphosphate-based light absorbance time course ([@B47],[@B48]). Interferon-β quantification was determined using the human Interferon β-specific ELISA (PBL Laboratories, NJ, USA, Cat. No. 41400-1) according to the manufacturer\'s protocol.

Determination of osmolarity
---------------------------

The osmolarity of ChoMaster® HTS medium supplemented with different [l]{.smallcaps}-arginine concentrations was assessed with a Vapro® according to the manufacturer\'s instructions (Wescor Inc., Logan, UT, USA).

*In vivo* methods
-----------------

CHO-K1 cells, engineered for [l]{.smallcaps}-arginine-controlled SEAP expression (CHO-ARG2-SEAP), were encapsulated into 400 μm alginate-poly-([l]{.smallcaps}-lysine)-alginate beads (200 cells/capsule) using the Inotech Encapsulator Research IE-50R (Inotech Biotechnologies Ltd, Basel, Switzerland) according to the manufacturer\'s protocol and the following parameters: 0.2 mm nozzle, 20 ml syringe at a flow rate of 405 units, nozzle vibration frequency 1024 Hz, voltage for bead dispersion 900 V. Seven hundred microliters of [l]{.smallcaps}-arginine-free ChoMaster® HTS containing 2 × 10^6^ encapsulated cells (10^4^ capsules/mouse) were injected intraperitoneally into mice (oncins France souche 1, Charles River Laboratories, France). One hour after implantation, [l]{.smallcaps}-arginine was administered by injection at doses ranging from 0 to 100 mg/kg. [l]{.smallcaps}-arginine was prepared for *in vivo* administration by diluting the [l]{.smallcaps}-arginine stock solution (see above) with an iso-osmotic 0.9% NaCl solution to obtain the appropriate concentrations. Control mice were implanted with capsules containing wild-type CHO-K1 cells. Seventy-two hours after implantation, the mice were sacrificed and their blood collected. For SEAP quantification, serum was isolated using a microtainer SST tube (Beckton Dickinson, Plymouth, UK) according to the manufacturer\'s protocol. All experiments involving mice were performed according to the European Community Council directive (86/609/EEC), approved by the French Ministry of Agriculture and Fishery (Paris, France) and performed by M.D-E.-B. at the Institut Universitaire de Technologie, IUTA, F-69622 Villeurbanne Cedex, France.

RESULTS
=======

Determination of the [l]{.smallcaps}-arginine concentration range compatible with host physiology and potential [l]{.smallcaps}-arginine-controlled gene expression
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

Since [l]{.smallcaps}-arginine plays a central role in the urea cycle, the synthesis of nitric oxide and for the synthesis of cytoplasmic and nuclear proteins ([@B49]), it is often the rate-limiting amino acid in fast-growing organisms ([@B50],[@B51]). In order to prevent [l]{.smallcaps}-arginine becoming a physiologic bottleneck or endogenous [l]{.smallcaps}-arginine interfering with ART-controlled transgene expression in mammalian cells, we exposed a CHO-K1-derived SEAP-expressing cell line \[CHO-ET~1~-SEAP~1~, ([@B10])\] to [l]{.smallcaps}-arginine concentrations ranging from 0 to 10 000 mg/l and scored SEAP levels and cell density after a 60 h cultivation period. A 10 mg/l [l]{.smallcaps}-arginine was sufficient to support robust wild-type-like cell growth with SEAP production levels equivalent to control cultivations in standard ChoMaster® HTS medium containing a default [l]{.smallcaps}-arginine concentration of 200 mg/l ([Figure 1](#F1){ref-type="fig"}). This observation is quantitatively comparable with physiologic plasma concentrations of [l]{.smallcaps}-arginine found in mice and humans \[∼17 mg/l, ([@B52])\]. Between 10 mg/l and 2 g/l of [l]{.smallcaps}-arginine, SEAP production and cell densities were comparable to populations cultivated in standard ChoMaster® HTS medium. At [l]{.smallcaps}-arginine concentrations above 2 g/l the culture media became hyperosmotic (\>310 mOsm) which compromised cell viability and titer ([Figure 1](#F1){ref-type="fig"}). Based on this data, we selected 10 mg/l and 1 g/l as low and high [l]{.smallcaps}-arginine concentrations in follow-up experiments. Figure 1.Impact of [l]{.smallcaps}-arginine on overall production capacity and cell density. CHO-ET~1~-SEAP~1~, constitutively expressing SEAP, were exposed to [l]{.smallcaps}-arginine concentrations ranging from 0 to 10 000 mg/l. SEAP production (black bars) and maximum cell densities (gray bars). Standard ChoMaster® HTS medium contains 200 mg/l [l]{.smallcaps}-arginine. For [l]{.smallcaps}-arginine concentration ranging from 0 to 2 g/l, the media is iso-osmotic (280 -- 310 mOsm). Above 2 g/l [l]{.smallcaps}-arginine, the media shifts into hypersomotic condition (\>310 mOsm).

Design of a [l]{.smallcaps}-arginine-responsive mammalian transcription control system
--------------------------------------------------------------------------------------

Capitalizing on the ArgR repressor of *Chlamydia pneumoniae*, which manages arginine metabolism by binding to specific operator sequences (O~ARG~) upstream of the *glnPQ* operon in a [l]{.smallcaps}-arginine-inducible manner, we have designed a [l]{.smallcaps}-arginine-regulated transgene control system (ART) which fine-tunes transgene transcription in mammalian cells. ART consists of two components, a [l]{.smallcaps}-arginine-regulated transactivator (ARG1) and an ARG1-specific synthetic promoter (P~ART1~): (i) ARG1 was designed by fusing ArgR C-terminally to the human NF-κB transactivation domain (ARG1, ArgR-p65; pSH120, P~SV40~-ARG1-pA) ([@B8],[@B39]). (ii) P~ART1~ was assembled by cloning an ArgR-specific operator module harboring two ARG boxes separated by a single base pair triplet (O~ARG~, AGTTTTCTTGGATTA[ATTGCATAAATATGATTT]{.ul}CAT[TATAAATAAATATGCATA]{.ul}AGAGGTCGGAGTG; predicted ARG boxes underlined) 5′ of a minimal version of the human cytomegalovirus immediate early promoter (P~hCMVmin~; P~ART1~, O~ARG~--P~hCMVmin~; pSH93, P~ART1~--SEAP-pA; [Figure 2](#F2){ref-type="fig"}A) ([@B15],[@B39]). Upon co-transfection of pSH120 (P~SV40~--ARG1-pA) and pSH93 (P~ART1~--SEAP-pA) into CHO-K1, SEAP expression remained repressed in the presence of 10 mg/l and could be induced by addition of [l]{.smallcaps}-arginine up to 1 g/l, suggesting that ARG1 binds and transactivates P~ART1~ in mammalian cells akin to [l]{.smallcaps}-arginine-triggered induction of the *glnPQ* operon by ArgR in *Chlamydia pneumoniae* ([@B39]) ([Figure 2](#F2){ref-type="fig"}B and C). Figure 2.Diagram of the ART regulation system. (**A**) The bacterial repressor ArgR of *Chlamydia pneumoniae*, fused to the human NF-κB transactivation domain (ARG1, ArgR-p65), is expressed in a constitutive manner under the control of the simian virus 40 promoter (P~SV40~). The [l]{.smallcaps}-arginine-responsive promoter (P~ART1~) harbors an ArgR-specific operator sequence (O~ARG~, capital letters, ARG boxes underlined) upstream of the minimal version of the cytomegalovirus immediate early promoter (P~hCMVmin~) and drives expression of a reporter gene (e.g. human secreted alkaline phosphatase, SEAP) in a [l]{.smallcaps}-arginine-induced manner. All expression units are terminated by a polyadenylation site (pA). Selected restriction sites are indicated: A, *Aat*II; B, *BssH*II; Ba, *BamH*I; E, *Eco*RI; H, *Hind*III; N, *Not*I; S, *Sbf*I; X, *Xba*I, Xh, *Xho*I. (**B**) At a low [l]{.smallcaps}-arginine concentration (10 mg/l), the ARG1 is in a low-affinity DNA binding state and does not interact with its specific operator sequence (O~ARG~); therefore, expression of the transgene remains silent. At a higher [l]{.smallcaps}-arginine concentration (1 g/l), the chimeric transactivator switches to a high-affinity conformation and activates transcription from P~hCMVmin~ upon binding to P~ART1~ through direct ARG1-O~ARG~ interaction, thus enabling the transcription of the reporter gene (e.g. SEAP). (**C**) CHO-K1 were transiently transfected with pSH120 (P~SV40~-ARG1-pA) and pSH93 (P~ART1~-SEAP-pA) and cultivated for 60 h in medium adjusted to [l]{.smallcaps}-arginine concentration ranging from 10 to 1000 mg/l before SEAP production was profiled. The induction factor of SEAP expression is indicated on the top of each bar.

Optimizing the ART system I---different [l]{.smallcaps}-arginine-dependent transactivator variants
--------------------------------------------------------------------------------------------------

Weber and colleagues ([@B9]) have demonstrated that the type of transactivation domain fused to the response regulator may impact overall regulation performance. To characterize potential alternatives to the p65 transactivation domain, we fused the *Chlamydia pneumoniae* [l]{.smallcaps}-arginine-dependent transactivator to the VP16 domain from *Herpes simplex* (ARG2) ([@B53]) and the transactivation domain of the human E2F4 (ARG3) ([@B54]) ([Figure 3](#F3){ref-type="fig"}A). For comparative analysis of the regulation performance, ARG1-, ARG2- and ARG3-encoding plasmids were co-transfected with pSH93 (P~ART1~-SEAP-pA) into CHO-K1 and SEAP production was profiled after cultivation for 60 h in medium containing either 10 mg/l or 1 g/l [l]{.smallcaps}-arginine (pSH120 and pSH93: 1.12 ± 0.12 U/l (10 mg/l [l]{.smallcaps}-arginine), 7.25 ± 0.39 U/l (1 g/l [l]{.smallcaps}-arginine); pSH91 and pSH93: 0.50 ± 0.07 U/l (10 mg/l [l]{.smallcaps}-arginine), 10.66 ± 0.09 U/l (1 g/l [l]{.smallcaps}-arginine); pSH121 and pSH93: 0.75 ± 0.22 U/l (10 mg/l [l]{.smallcaps}-arginine), 2.76 ± 0.08 U/l (1 g/l [l]{.smallcaps}-arginine). SEAP expression values of the different transactivator--promoter combinations exhibited varied performance characteristics with the basal expression of ARG2 being slightly lower compared to ARG1 and ARG3 exhibiting the poorest performance characterized by lower maximum and higher basal expression levels. Taken together, co-transfection of P~ART1~ with ARG2 enabled the highest induction performance for SEAP expression ([Figure 3](#F3){ref-type="fig"}B--D, SEAP values with P~ART1~). Figure 3.Regulation performance of P~ART1~ variants with different [l]{.smallcaps}-arginine-dependent transactivators. (**A**) Schematic representation of the different [l]{.smallcaps}-arginine-dependent transactivators. The bacterial repressor ArgR of *Chlamydia pneumoniae*, fused to human E2F4 (ARG3, ArgR-E2F4) or *H. simplex* VP16 (ARG2, ArgR-VP16). The expression of both transactivators is driven by the simian virus 40 promoter (P~SV40~). Selected restriction sites are indicated: B, *BssH*II; Ba, *BamH*I; E, *Eco*RI; H, *Hind*III; N, *Not*I; Sa, *Sal*I; X, *Xba*I. The [l]{.smallcaps}-arginine-responsive promoters harboring 0 (P~ART1~), 2 (P~ART2~), 4 (P~ART3~), 6 (P~ART4~), 8 (P~ART5~) and 10 (P~ART6~) bp linkers between the operator sequence and the minimal promoter were co-transfected with [l]{.smallcaps}-arginine-dependent transactivators containing the (**B**) human NF-κB (ARG1, ArgR-p65), (**C**) human E2F4 (ARG3, ArgR-E2F4) and (**D**) *H. simplex* VP16 (ARG2, ArgR-VP16) transactivation domains. Cells were grown at low (10 mg/l) or high (1 g/l) [l]{.smallcaps}-arginine concentrations and SEAP production was assessed 60 h after transfection. The regulation factor for each promoter/transactivator combination is specified.

Optimizing the ART system II---promoter variants which differ in the distance between ARG box operator and minimal promoter
---------------------------------------------------------------------------------------------------------------------------

The relative spacing of promoter components such as operator and minimal promoter influences the assembly of the transcription machinery and impacts basal as well as maximum transcription levels ([@B55],[@B56]). We have, therefore, engineered P~ART1~ variants containing an increasing number of 2 bp insertions between O~ARG~ and P~hCMVmin~ which modifies the distance and the torsion angle between these promoter components. While P~ART1~ harbors the default 21 bp between the putative ARG box (O~ARG~) and P~hCMVmin~, P~ART2~ (O~ARG~-2 bp-P~hCMVmin~), P~ART3~ (O~ARG~-4 bp-P~hCMVmin~), P~ART4~ (O~ARG~-6 bp-P~hCMVmin~), P~ART5~ (O~ARG~-8 bp-P~hCMVmin~) and P~ART6~ (O~ARG~-10 bp-P~hCMVmin~) contain additional 2, 4, 6, 8 and 10 bp between O~ARG~ and P~hCMVmin~. All promoters were cloned 5' of SEAP resulting in a genetic configuration which were isogenic to pSH93 (see [Table 1](#T1){ref-type="table"}). 60 h after co-transfection of pSH120 (P~SV40~-ARG1-pA), pSH121 (P~SV40~-ARG3-pA) or pSH91 (P~SV40~-ARG2-pA) and either pSH93 or one of its isogenic derivatives into CHO-K1 and cultivation in the presence of 10 mg/l or 1 g/l, SEAP production was quantified. When co-transfected with pSH120 or pSH91, P~ART2~ drove maximum SEAP production while basal expression was minimal for P~ART6~. Comparing P~ART2~ through P~ART6~, maximum SEAP expression levels seem to decrease with increasing distance of O~ARG~ and P~hCMVmin~ ([Figure 3](#F3){ref-type="fig"}B and D). For co-transfection of CHO-K1 with pSH121, E2F4 transactivation domain mediated the poorest regulation performance, characterized by higher leakiness (10 mg/l [l]{.smallcaps}-arginine) and lower maximum expression levels (1 g/l [l]{.smallcaps}-arginine) ([Figure 3](#F3){ref-type="fig"}C). Overall, P~ART1~ showed an optimal balance between basal and maximum expression.

Optimizing the ART system III---promoter variants which differ in the number of ARG box operator modules
--------------------------------------------------------------------------------------------------------

Increasing the number of tandem operator modules within a trigger-inducible promoter may increase maximum expression levels as more transactivators can be recruited to the promoter ([@B57]). The transcriptional activity of the promoters harboring the operator in a monomeric (pSH117, P~ARTm1~-SEAP-pA; P~ARTm1~, *Asc*I-O~ARG~-*Mlu*I-0bp-P~hCMVmin~), dimeric (pSH119, P~ARTm2~-SEAP-pA; P~ARTm2~, *Asc*I-O~ARG~-7bp-O~ARG~--*Mlu*I-0bp-P~hCMVmin~), trimeric (pSH126, P~ARTm3~-SEAP-pA; P~ARTm3~, *Asc*I-O~ARG~-7bp-O~ARG~-7bp-O~ARG~--*Mlu*I-0bp-P~hCMVmin~) or tetrameric (pSH127, P~ARTm4~-SEAP-pA; P~ARTm4~, *Asc*I-O~ARG~-7bp-O~ARG~-7bp-O~ARG~--7bp-O~ARG~-*Mlu*I-0bp-P~hCMVmin~) configuration were assessed in CHO-K1 cells co-transfected with pSH91 (pSH91, P~SV40~-ARG2-pA). In general, increasing the number of operator modules resulted in higher maximum expression levels but also higher basal expression ([Figure 4](#F4){ref-type="fig"}A). Having defined the parameters for optimal transgene regulation, the ART system was further validated for expression of the multiple sclerosis therapeutic interferon-β. Interferon-β was cloned downstream of P~ART1~ (pSH113, P~ART1~-INF-β-pA), which was transactivated by ARG2 (pSH91, P~SV40~-ARG2-pA). CHO-K1 transiently co-transfected with pSH113 and pSH91 enabled adjustable INF-β expression, when exposed to [l]{.smallcaps}-arginine concentrations ranging from 10 mg/l to 1g/l ([Figure 4](#F4){ref-type="fig"}B). Figure 4.(**A**) Validation of P~ART1~ variants containing a different number of ARG-specific operator modules. SEAP expression vector encoding [l]{.smallcaps}-arginine-responsive promoters harboring monomeric (pSH117, P~ARTm1~-SEAP-pA; P~ARTm1~, *Asc*I-O~ARG~-*Mlu*I-0bp-P~hCMVmin~), dimeric (pSH119, P~ARTm2~-SEAP-pA; P~ARTm2~, *Asc*I-O~ARG~-7bp-O~ARG~--*Mlu*I-0bp-P~hCMVmin~), trimeric (pSH126, P~ARTm3~-SEAP-pA; P~ARTm3~, *Asc*I-O~ARG~-7bp-O~ARG~-7bp-O~ARG~--*Mlu*I-0bp-P~hCMVmin~) or tetrameric (pSH127, P~ARTm4~-SEAP-pA; P~ARTm4~, *Asc*I-O~ARG~-7bp-O~ARG~-7bp-O~ARG~--7bp-O~ARG~-*Mlu*I-0bp-P~hCMVmin~) operator modules were co-transfected with pSH91 (P~SV40~-ARG2-pA) into CHO-K1 and SEAP production was profiled after 60 h. The induction factor is shown on the top of each bar. (**B**) Dose--response profile of interferon-β expression in CHO-K1. Cells were transiently co-transfected with pSH113 (pSH113, P~ART1~-INF-β-pA) and pSH91 (P~SV40~-ARG2-pA) and grown for 48 h at different [l]{.smallcaps}-arginine concentrations before quantification of the interferon-β production in the supernatant. Fold induction is shown on the top of each bar.

Validation of the ARG2---P~ART1~ configuration in different cell lines
----------------------------------------------------------------------

Since the combination of ART2 and P~ART1~ provided the best combination of low leaky and maximum expression levels, we sought to further validate this system. Immortalized cell lines of human, rodent and monkey origin were co-transfected with pSH91 and pSH93. Sixty hours post transfection, cells exposed to 10 mg/l [l]{.smallcaps}-arginine displayed low SEAP expression, whereas 1 g/l [l]{.smallcaps}-arginine induced high-level production of the reporter gene ([Table 2](#T2){ref-type="table"}). Moreover, expression integrity of ARG2 in mammalian cells was confirmed by western blot analysis using HEK293-T transiently transfected with pSH91 (P~SV40~-ARG2-pA) ([Figure 5](#F5){ref-type="fig"}). Figure 5.Western blot analysis of ARG2 expression in HEK-293T cells transfected with pSH91 (pSH91, P~SV40~-ARG2-pA) and cultivated for 60 h. Lane 1, lysate from HEK-293T transfected with pSH91 (pSH91, P~SV40~-ARG2-pA); lane 2, lysate from untransfected control cells. The 35 kDa band, indicative for the fusion protein ARG2 is shown with a black arrow. The loading control (tubulin-α, 57kDa) is indicated with an open arrow. Migration of molecular mass markers (kDa) is indicated on the left. Table 2.Quantitative SEAP expression profiles under the control of P~ART1~ in immortalized cell lines with pSH91, an ARG2 encoding vector and pSH93, a P~ART1~-driven SEAP expression cassette, SEAP expression levels were determined in cell culture media (U/l), 60 h after co-transfectionCell lineSEAP activity (U/l)10 mg/l [l]{.smallcaps}-arginine1 g/l [l]{.smallcaps}-arginineCHO-K10.69 ± 0.458.08 ± 0.80HEK-293T1.67 ± 0.2521.83 ± 3.19NIH/3T3(0.72 ± 0.39) × 10^−3^(25.05 ± 2.00) × 10^−3^COS-70.15 ± 0.072.47 ± 0.20HT-10800.04 ± 0.000.72 ± 0.06

Autoregulated [l]{.smallcaps}-arginine-inducible transgene expression in CHO-K1
-------------------------------------------------------------------------------

The ART system was also validated in an autoregulated positive feedback configuration enabling one-step installation of regulated transgene expression in mammalian cells using a single-vector format. This configuration mediates simultaneous expression of transactivator and transgene, both driven by the transactivator-dependent promoter and was found to be instrumental for the design of noise resistant gene networks ([@B58]). Leaky transcripts mediated by the P~ART1~ promoter initiate production of relatively few transactivator molecules which trigger full expression of P~ART1~-driven transgenes in the presence of [l]{.smallcaps}-arginine. SEAP expression was assessed in CHO-K1 transiently transfected with pSH122 (pSH122, P~ART1~-SEAP-IRES~PV~-ARG2-pA, [Figure 6](#F6){ref-type="fig"}A). P~ART1~ transcription mediates basal SEAP and ARG2 production which results in ARG2-triggered auto-induction of the dicistronic expression unit in the presence of high [l]{.smallcaps}-arginine concentrations ([Figure 6](#F6){ref-type="fig"}B). Figure 6.(**A**) Diagram of the autoregulated [l]{.smallcaps}-arginine-inducible SEAP expression vector (pSH122). pSH122 harbors the [l]{.smallcaps}-arginine-responsive promoter (P~ART1~) which drives transcription of the dicistronic expression unit encoding the the human placental alkaline phosphatase (SEAP) in the first and the [l]{.smallcaps}-arginine-dependent transactivator (ARG2) in the second cistron. Whereas translation of SEAP occurs via a classic cap-dependent mechanism, translation-initation of ARG2 is mediated by an internal ribosome entry site of polioviral origin (IRES~PV~). pA is the polyadenylation signal. Selected restriction sites are indicated: A, *Aat*II; E, *Eco*RI; N, *Not*I; X, *Xba*I, Xh, *Xho*I. (**B**) pSH122 was transiently transfected into CHO-K1, cultivated in media containing 10 mg/l or 1 g/l [l]{.smallcaps}-arginine prior to SEAP quantification. Fold induction is indicated on the top of the bars.

Regulation performance of [l]{.smallcaps}-arginine derivatives and secondary products
-------------------------------------------------------------------------------------

In order to assess the specificity of ART-controlled transgene expression, we cultivated CHO-K1, co-transfected with pSH91 (P~SV40~-ARG2-pA) and pSH93 (P~ART1~-SEAP-pA), in the presence of increasing concentrations of [l]{.smallcaps}-arginine and several of its derivatives ([l]{.smallcaps}-canavanine, [l]{.smallcaps}-homoarginine, [l]{.smallcaps}-arginine methyl ester and [l]{.smallcaps}-arginine ethyl ester) and secondary metabolic products ([l]{.smallcaps}-ornithine, [l]{.smallcaps}-citrulline, agmatine) and profiled SEAP production after 60 h ([Figure 7](#F7){ref-type="fig"}A). Of all these compounds only [l]{.smallcaps}-arginine and its methyl and ethyl esters induced SEAP to significant levels while retaining typical dose--response characteristics ([Figure 7](#F7){ref-type="fig"}B). Figure 7.Impact of [l]{.smallcaps}-arginine and its derivatives on ART-controlled gene expression. (**A**) The structure of the [l]{.smallcaps}-arginine derivatives used in this study. (**B**) Sixty hours after co-transfection with pSH91 (P~SV40~-ARG2-pA) and pSH93 (P~ART1~-SEAP-pA), SEAP expression of CHO-K1 was measured. Cells were incubated in cell culture media containing 10 mg/l [l]{.smallcaps}-arginine and supplemented with 57.4, 574 or 5740 μM of [l]{.smallcaps}-arginine, [l]{.smallcaps}-ornithine, [l]{.smallcaps}-citrulline, agmatine, [l]{.smallcaps}-homoarginine, [l]{.smallcaps}-arginine methyl ester, [l]{.smallcaps}-arginine ethyl ester or [l]{.smallcaps}-canavanine (5740 μM correspond to 1 g/l [l]{.smallcaps}-arginine).

Adjustability and reversibility of the ART-controlled transgene expression
--------------------------------------------------------------------------

In order to determine the adjustability and reversibility of [l]{.smallcaps}-arginine-controlled transgene expression, we generated a stable CHO-K1-derived cell line transgenic for constitutive ARG2 expression and P~ART1~-controlled SEAP production (CHO-ARG2-SEAP). CHO-ARG2-SEAP was cultivated for 60 h in medium containing increasing concentrations of [l]{.smallcaps}-argininine before SEAP was profiled in the culture supernatant. As shown in [Figure 8](#F8){ref-type="fig"}A, SEAP expression could be precisely adjusted to specific levels which correlate with particular [l]{.smallcaps}-arginine doses. Besides adjustability, rapid response kinetics and reversibility are key assets for a mammalian transgene control system. In order to assess the expression kinetics of the ART system, we profiled both SEAP expression and cell growth for over 96 h. CHO-ARG2-SEAP cells cultivated in medium supplemented with either 10 mg/l or 1 g/l [l]{.smallcaps}-arginine displayed similar growth rates, whereby significant SEAP expression was detected only in CHO-ARG2-SEAP cultivated in the presence of 1 g/l [l]{.smallcaps}-arginine ([Figure 8](#F8){ref-type="fig"}B). The reversibility was determined by cultivating CHO-ARG2-SEAP for up to 1 week while alternating the inducing (1 g/l) or repressing (10 mg/l) culture condition every other day. The SEAP production profiles revealed reproducible sequential expression kinetics, precise reversibility and tight repression after ON-to-OFF switching ([Figure 8](#F8){ref-type="fig"}C). Figure 8.Dose-dependent control of gene expression and reversibility. (**A**) CHO-ARG2-SEAP cells, transgenic for [l]{.smallcaps}-arginine-controlled SEAP expression, were cultured for 60 h at different [l]{.smallcaps}-arginine concentrations before SEAP expression profiling. (**B**) Growth (line) and production (bars) kinetics of ART-controlled SEAP production were scored for CHO-ARG2-SEAP for 96 h. (**C**) Reversibility of [l]{.smallcaps}-arginine-mediated transgene expression following periodic addition and removal of [l]{.smallcaps}-arginine. CHO-ARG2-SEAP cells (110 000 cells/ml) were cultivated in 10 mg/l (dotted line) or in 1 g/l (solid line) [l]{.smallcaps}-arginine at time 0. Every 48 h (vertical arrows), cells were readjusted to 110 000 cells/ml and grown in fresh media with reversed [l]{.smallcaps}-arginine concentrations.

[l]{.smallcaps}-arginine-inducible transgene expression in mice
---------------------------------------------------------------

For validation of ART-controlled transgene expression *in vivo*, we have encapsulated CHO-ARG2-SEAP into coherent alginate-poly-([l]{.smallcaps}-lysine)-alginate microcapsules (200 cells per capsule) and implanted them (10^4^ capsules per mouse) intraperitoneally into mice. Implanted mice were given a daily dose of [l]{.smallcaps}-arginine ranging from 0 to 100 mg/kg for 72 h before quantifying serum SEAP levels. The SEAP levels reached in the serum of treated mice was adjustable and dependent on the injected [l]{.smallcaps}-arginine dose. The serum SEAP levels of control mice implanted with microencapsulated CHO-K1 (data not shown) or mice implanted with microencapsulated CHO-ARG2-SEAP but not receiving exogenous [l]{.smallcaps}-arginine showed insignificant SEAP expression level ([Figure 9](#F9){ref-type="fig"}A). In parallel, the experiment was also performed *in vitro* with the same batch of encapsulated cells, which confirmed the dose--response characteristics of microencapsulated CHO-ARG2-SEAP ([Figure 9](#F9){ref-type="fig"}B). Figure 9.ART-inducible SEAP expression in mice. (**A**) CHO-ARG2-SEAP cells were microencapsulated in alginate-poly-([l]{.smallcaps}-lysine)-alginate beads and implanted intraperitoneally into female OF1 mice (2 × 10^6^ cells per mouse). Implanted mice were exposed daily to different arginine concentrations. 72 h post-implantation, the level of SEAP in the serum of mice serum was determined. (**B**) SEAP expression of microencapsulated CHO-ARG2-SEAP cells cultured *in vitro*. CHO-ARG2-SEAP microencapsulated cells, originating from the same batch as for the transplantation in mice, were cultured for 72 h at the indicated [l]{.smallcaps}-arginine concentration before quantifying SEAP expression.

DISCUSSION
==========

Currently available transgene control systems have been designed for optimal regulation performance *in vitro* or in a mouse model ([@B59]). To enable interference-reduced operation within a complex biochemical reaction network of the host cell, heterologous or modified endogenous transcription factors have been engineered to modulate transcription of specific target promoters ([@B60],[@B61]). Initially, inducer molecules only required reasonable pharmacokinetics and needed to be non-toxic at regulation-effective concentrations, criteria which was best met by clinically licensed small-molecule drugs ([@B16],[@B18],[@B62]). However, the use of clinically licensed substances to control biopharmaceutical manufacturing of difficult-to-produce protein pharmaceuticals fails to comply with administrative regulations or requires prohibitive downstream processing standards ([@B33],[@B63],[@B64]). Also, long-term administration of drugs at (sub-)clinical doses has been associated in many cases with side-effects which limits their use in future gene therapy trials ([@B26],[@B28; @B29; @B30]). In contrast, physiologic molecules such as amino acids are FDA-licensed media components and an integral part of host metabolism. Due to possible interference effects, such physiologic trigger molecules have so far not been considered for transgene control.

As an obligate intracellular pathogen, *Chlamydia pneumoniae* has evolved to optimally plug in its metabolism into the biochemical networks of host cells ([@B38]). As a major part of this metabolic crosstalk, the biosensor ArgR quantifies [l]{.smallcaps}-arginine levels and manages import of this amino acid ([@B40]). It is, therefore, reasonable to assume that the sensitivity of ArgR is attuned to physiologic [l]{.smallcaps}-arginine levels of mammalian cells. Indeed, ART-controlled expression of reporter and product genes shows excellent regulation performance (rapid induction kinetics, full adjustability, reproducible reversibility) in different cell lines as well as in mice with an arginine concentration window between 10 mg/l (required to maintain metabolism, transgene repressed) and 1 g/l (full induction). The [l]{.smallcaps}-arginine level in the plasma of mice is around 17 mg/l, which is well below the threshold concentration required to fully activate the ART system ([@B52]). By default, ART is an ON-type system, which means that it is only induced in the presence of increased [l]{.smallcaps}-arginine levels and remains repressed at physiologic concentrations of this amino acid.

ART is exclusively regulated by [l]{.smallcaps}-arginine and its ester forms which are rapidly converted to [l]{.smallcaps}-arginine by endogenous esterases ([@B65]). Secondary products of the [l]{.smallcaps}-arginine metabolism or the synthetic [l]{.smallcaps}-homoarginine failed to regulate the ART system. Even [l]{.smallcaps}-canavanine, which is stereochemically similar to [l]{.smallcaps}-arginine and was shown to fit in the amino acid binding pocket of ArgR was unable to modulate ART-controlled transgene expression ([@B66]).

Since [l]{.smallcaps}-arginine is a licensed component of cell culture media, the ART system will be a extremely valuable tool for the biomanufacturing of therapeutic proteins. Moreover, [l]{.smallcaps}-arginine is considered to be compatible with prolonged therapeutic use. In fact, [l]{.smallcaps}-arginine is currently therapeutically administered for pulmonary hypertension of newborns ([@B67]). It also improves endothelial function in animal models of hypercholesterolaemia and atherosclerosis with no life-threatening side-effects reported so far ([@B68]).

As a prototype transgene control system responsive to a physiologic trigger molecule, the ART system has shown that metabolic and synthetic control circuits can functionally co-exist while sharing the same inducer. Although such systems may be of immediate use in gene-function analysis, gene network design as well as for biopharmaceutical manufacturing, the ART may develop its highest impact in future therapies: synchronization of therapeutic gene expression with fluctuations of endogenous molecules or the self-sufficient treatment of a pathological situation by exploiting signal molecules for a self-controlling genetic intervention are highly appealing strategies for future gene therapy applications.
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[^1]: ArgR, transactivator of the *C. pneumoniae* CWL029 of the *glnPQ* operon; ARG1, [l]{.smallcaps}-arginine-dependent transactivator (ArgR-p65); ARG2, [l]{.smallcaps}-arginine-dependent transactivator (ArgR-VP16); ARG3, [l]{.smallcaps}-arginine-dependent transactivator (ArgR-E2F4); E2F4, transactivation domain of the human E2F4; ET1, macrolide-dependent transactivator (E-VP16); ET2, macrolide dependent transactivator (E-p65); ET3, macrolide dependent transactivator (E-E2F4); ETR, operator module specific for MphR(A); IRES~PV~, internal ribosome entry site of polioviral origin; NF-κB, human transcription factor; O~ARG~, ArgR-specific operator; p65, transactivation domain of NF-κB; pA, SV40-derived polyadenylation site; P~ART1-6~, [l]{.smallcaps}-arginine-responsive promoters containing different spacers between O~ARG~ and P~hCMVmin~; P~ARTm1-4~, [l]{.smallcaps}-arginine-responsive promoters containing one (P~ARTm1~), two (P~ARTm2~), three (P~ARTm3~) or four (P~ARTm4~) operator sequences upstream of P~hCMVmin~; P~hCMV~, human cytomegalovirus immediate early promoter; P~ETR5-9~, macrolide-responsive promoters containing different spacers between ETR and P~hCMVmin~; P~hCMVmin~, minimal version of the human cytomegalovirus promoter; P~SV40~, constitutive simian virus 40 promoter; SEAP, human placental secreted alkaline phosphatase; VP16, *H. simplex* virus-derived transactivation domain.
